Status:
RECRUITING
Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients
Lead Sponsor:
Mansoura University
Conditions:
Chronic Kidney Disease(CKD)
Anemia, Kidney Disease, Chronic
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, primarily used in the management of type 2 diabetes mellitus. Emerging research suggests that SGLT2 inhibitors may offer additiona...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Adults aged ≥ 18 years with CKD stage III or IV.
- Patients with anemia of CKD and a hemoglobin level \< 11.5 g/dL
- Patients are receiving erythropoiesis-stimulating agent therapy.
- Exclusion criteria
- Anemia due to causes other than chronic kidney disease, such as pernicious anemia, thalassemia, sickle cell anemia, or myelodysplastic syndromes.
- Patients with severe ketosis, diabetic coma, severe infection, perioperative complications, or severe trauma.
- Patients with acute heart failure, acute myocardial infarction, or stroke occurring within 6 months before enrollment in the trial.
- Patients with current malignancies or a history of malignancy within the past 2 years.
- Diagnosed with pure red cell aplasia.
- Patients with severe gastrointestinal bleeding.
- Pregnant or lactating females.
Exclusion
Key Trial Info
Start Date :
April 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2025
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06897605
Start Date
April 1 2025
End Date
October 1 2025
Last Update
April 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Urology and Nephrology Center
Al Mansurah, Egypt